![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
-
Article
Open AccessPrognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
Secondary AML (sAML), defined by either history of antecedent hematologic disease (AHD) or prior genotoxic therapy (tAML), is classically regarded as having worse prognosis than de novo disease (dnAML). Clinic...
-
Article
Open AccessEffect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
-
Article
Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients
-
Article
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm
-
Article
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies
-
Article
Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia
-
Article
Need for routine examination of left ventricular ejection fraction in patients with AML
-
Article
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia
-
Article
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
-
Article
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials
-
Article
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
Outcomes with “7 + 3” are often unsatisfactory in acute myeloid leukemia (AML). Trials demonstrating improved outcomes with high-dose cytarabine, addition of cladribine, or escalated anthracycline doses prompt...
-
Article
New drugs in AML: uses and abuses